Insulin enhances RANKL-induced osteoclastogenesis via ERK1/2 activation and induction of NFATc1 and Atp6v0d2
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Ju Hee | - |
dc.contributor.author | Lee, Jae Yoon | - |
dc.contributor.author | Joung, Seung Hee | - |
dc.contributor.author | Oh, Yoon Taek | - |
dc.contributor.author | Kim, Hong Sung | - |
dc.contributor.author | Lee, Na Kyung | - |
dc.date.accessioned | 2021-08-11T19:24:52Z | - |
dc.date.available | 2021-08-11T19:24:52Z | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 0898-6568 | - |
dc.identifier.issn | 1873-3913 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10079 | - |
dc.description.abstract | Insulin is one of the main factors affecting bone and energy metabolism, however, the direct effect of insulin on osteoclast differentiation remains unclear. Thus, in order to help elucidate that puzzle, the authors investigated the roles and regulatory mechanisms of insulin on osteoclasts differentiation. Co-stimulation with insulin and RANKL significantly enhanced the number of larger (>100 mu m) osteoclastic cells and of TRAP-positive multinucleated cells compared with treatment by RANKL alone. Conversely, the insulin receptor shRNA markedly decreased osteoclast differentiation induced by insulin and RANKL. Insulin treatment significantly activated ERK1/2 MAP kinase as well as markedly induced the expression of NFATc1, an osteoclast marker gene, and Atp6v0d2, an osteodast fusion-related gene. The pretreatment of PD98059, an ERK1/2 inhibitor, or insulin receptor shRNA effectively suppressed osteoclast differentiation and, in addition, blocked the expression of NFATcl and Atp6vod2 induced by insulin stimulation. These data reveal insights into the regulation of osteoclast differentiation and fusion through ERK1/2 activation and the induction of NFATc1 and Atp6v0d2 by insulin. (C) 2015 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Insulin enhances RANKL-induced osteoclastogenesis via ERK1/2 activation and induction of NFATc1 and Atp6v0d2 | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.cellsig.2015.09.002 | - |
dc.identifier.scopusid | 2-s2.0-84941287090 | - |
dc.identifier.wosid | 000367486400001 | - |
dc.identifier.bibliographicCitation | Cellular Signalling, v.27, no.12, pp 2325 - 2331 | - |
dc.citation.title | Cellular Signalling | - |
dc.citation.volume | 27 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2325 | - |
dc.citation.endPage | 2331 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | GLYCOGEN-SYNTHASE KINASE-3 | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | PROTEIN-KINASE | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | DC-STAMP | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordPlus | FUSION | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | OSTEOBLAST | - |
dc.subject.keywordAuthor | Osteoclast differentiation | - |
dc.subject.keywordAuthor | Insulin | - |
dc.subject.keywordAuthor | ERK1/2 | - |
dc.subject.keywordAuthor | NFATcl | - |
dc.subject.keywordAuthor | Atp6v0d2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.